

LINOVERA®

TECHNICAL FILE





ADMINISTRATIVE INFORMATION			
HEAD OFFICE ADDRESS	B. Braun Medical S.A. Carretera de Terrassa, 121. 08191 Rubi. Barcelona, Spain		
SBA & PRODUCT MANAGER	Wound Management, Louis vanden Schrieck		
SAFETY OFFICER MEDICAL DEVICES	Stephan Krause		
LAST UPDATE	21/04/2021		

DESCRIPTION, COMPOSITION AND PROPERTIES OF THE DEVICE			
COMMON NAME (FAMILY)	Skin prevention (567)		
TRADE NAME	Linovera®		
REFERENCES	450336, 491751, 492742, 492795, 492796, 492797, 492808, 492831, 492832, 492833,		
(SPECIFIC REFERENCES BY COUNTRY)	480060, 480080,480082, 467933, 468155, 468156, 468157, 468157FR, 488354,		
	492736, 492737, 492738, 492739, 492740, 492741, 492810, 492972, 450081		
GMDN CODE	57966 – Pressure ulcer topical dressing		
MEDICAL CLASS	lla		
DESCRIPTION OF THE DEVICE	Hyperoxygenated essential fatty acids (HOFA) present in the composition of Linovera® favor blood microcirculation, reducing the risk of ischemia and facilitating the renewal of epidermal cells, increasing the resistance of the skin against the agents that cause pressure ulcers. At the same time they protect against friction, reduce skin fragility and prevent dehydration of the skin. In addition, thanks to their antioxidant activity, they reduce the damage caused by free radicals. Linovera® also contains Aloe Barbadensis and Asian Centella. Aloe Barbadensis, also known as Aloe Vera, helps condition the skin and acts as emollient and humectant. Asian Centella also acts as a skin conditioner and has a toning and soothing effect on the skin.		

	Components	Function	
COMPOSITION OF THE DEVICE	Sunflower Hyperoxigenated Fatty Acids	Emollient	
	Aloe Barbadensis	Skin conditioning, Emollient, Humectan	
	Rosemary Essence	Organoleptic characteristics	
	Asian Centella	Skin conditioning, toning and soothing	
	effect on the skin.		
PROPERTIES OF THE DEVICE	Hyperoxygenated fatty acids from sunflower oil and vegetable extracts.		
KEY DRIVERS & INDICATIONS			
KEY DRIVERS & INDICATIONS	Increase blood microcirculation, reducing	the risk of ischemia	
KEY DRIVERS & INDICATIONS	Increase blood microcirculation, reducing Facilitate the renewal of epidermal cells	the risk of ischemia	
KEY DRIVERS & INDICATIONS			
	Facilitate the renewal of epidermal cells	ermis	
	Facilitate the renewal of epidermal cells Enhance the cellular cohesion of the epid	ermis	
KEY DRIVERS & INDICATIONS KEY DRIVERS	Facilitate the renewal of epidermal cells Enhance the cellular cohesion of the epid Increase the resistance of the skin agains	ermis	
	Facilitate the renewal of epidermal cells Enhance the cellular cohesion of the epid Increase the resistance of the skin agains Prevent skin dehydration	ermis	
	Facilitate the renewal of epidermal cells Enhance the cellular cohesion of the epid Increase the resistance of the skin agains Prevent skin dehydration Protect against friction	ermis	

STERILIZATION PROCESS: REPORT			
STERILE MD: YES/NO	No		
STERILIZATION METHOD	N/A		

CONSERVATION AND STORAGE CONDITIONS			
STORAGE CONDITIONS	5° – 25° C. Do not cool. Do not freeze. Dispose of the product in accordance with local regulations.		
TRANSPORT CONDITIONS	5° - 25°C. Do not cool. Do not freeze.		
SHELF LIFE	E 2 years from date of manufacture		


SAFETY IN USE			
TECHNICAL: MRI, X-RAY DETECTABLE	N/A		
ORGANIC	DEHP, phthalate free		
BIOCOMPATIBILITY	Doc References Linovera IIa DTP-6.2.AN.1		
	Council Directive 93/42/EEC		
	UNE-EN ISO 13485:2018		
	UNE-EN ISO 14971:2012		
	UNE EN ISO 14698-1: 2004		
	UNE-EN ISO 14644-2:2016		
STANDARDS & REQUIREMENTS	UNE-EN ISO 1041:2009+A1:2014		
	UNE-EN ISO 15223-1:2016		
	UNE-EN ISO 10993-1:2018		
	MEDDEV 2.7.1. Rev.·4		
	ICH Guideline Q1A (R2)		
	European Pharmacopeia		

RECOMMENDED USE	
	Yes, presence of IFU Linovera_IIa DTP-2.2.AN.1
IFU: YES/NO PRECAUTION OF USE CONTRAINDICATION	Precaution of use: Store the product in the original pack. Protect the container from direct sunlight. Wash your hands before and after using the product. The use of gloves is recommended. External use. Do not ingest. Avoid contact with the eyes. The product is indicated for adults. Do not use after the expiry date indicated in the bottle and the box.
	Contraindication: Do not use in case of known hyper sensibility to any of the ingredients exists. Adverse reactions: Cutaneous manifestations may appear in patients allergic to any of the components. In principle, they are not serious and cease when the application of the product is interrupted or with the use of antihistamines and/or corticoids.

ADDITIONAL PRODUCT INFORMATION	
REUSABLE/SINGLE USE DEVICE	Reusable. Use in combination with Askina® Heel for optimal protection for non-broken skin of the heel area against pressure ulcers.

PACKAGING & REFERENCES

Transport box for dispatching and additional protection against damage during transportation.



PACKAGING & PRODUCT LABEL



REFERENCES

Reference	Description	Size	Quantity per box
Specific references by country	Linovera®	10 ml	10
480060	Linovera®	20 ml	10
Specific references by country	Linovera®	30 ml	1
450081	Linovera®	50 ml	10

This document, its contents, including institutional data, information, trademarks and logos mentioned herein are the exclusive property of B. Braun.

Any representation and / or reproduction, total or partial, of this document and its contents without the express prior consent of B. Braun, is strictly prohibited and constitutes an infringement of the intellectual property rights of B. Braun.

B. Braun Medical | SAS with a share capital of 31 000 000 € | RCS Nanterre 562050856 www.bbraun.com/wound-management